Haier Biomedical saves lives by moving the blood bank right beside the patient

QINGDAO, China, Sept. 12, 2018 /PRNewswire/ -- Transfusion medicine has been around and under constant improvement for more than 300 years and and nowadays its delivery system of clinical blood has witnessed a landmark change. In order to address such blood-related issues as blood safety, its source and efficacy, China-based Haier Biomedical has co-created the world's first U-Blood platform ecosystem. It fundamentally ensures the safety of clinical blood and the sharing of blood resources, offering a value-added user experience for all parties involved.

Countries around the world have been striving continually to improve their clinical blood services. And the US, being the leader in healthcare industry, has launched an advanced blood management solution. By moving type O emergency blood to the operating room, it vastly reduces the time for transferring the needed life-saving substance to patients' side. With its proven efficiency, it has recently been deployed at Johns Hopkins Hospital.

Under that circumstance, Haier Biomedical's U-Blood solution has vastly improved the efficiency of blood banks by literally placing the blood bank to where it is needed most - right next to the patient's bed, which pushes the efficiency to a new level well beyond the current US standards. Through innovations in RFID IoT technology, the management model has shifted from centralized to decentralized type. The new model innovatively moves smart blood refrigerators to the operating room, hospital ward and the ambulance, achieving the end-to-end monitoring and traceability of all blood information. As a result of that, the blood is instantly accessible at hand, cutting off the valuable and life-saving time needed to deliver the blood to the patient. In addition, the Blood which is not used during the course of the surgery can be restored to the blood bank via the U-Blood monitoring equipment, which ensures true sharing of blood information and increases the hospital's surgery capacity.

In order to further improve the blood use experience, efforts are being made to provide the precise amount of blood needed for each transfusion by developing a customized and personalized program. Furthermore, with the application of big data and artificial intelligence (AI), the patient's consumption of blood will be comprehensively evaluated. And there is a tailored blood use program developed for monitoring the patient's condition and diagnostic data across the entire U-Blood platform ecosystem. For example, what may have been previously required for four units of blood can be reduced to a precise need of two, as a result of a profile generated via AI, avoiding the overuse and waste of blood and accelerating the patient's recovery.

According to authoritative analysis made by experts in the industry, U-Blood has created a new blood use model and experience which is worthy of applying around the world. To be more specific, in some recent use cases, has, at the Affiliated Hospital of Qingdao University and at the Chinese PLA General Hospital (301 Hospital) in Beijing, the U-Blood has proved its ability to offer values to hospitals, stakeholders and especially the customers. In a word, on the one hand it increases the efficiency of clinical blood use, at which blood can be acquired within one minute during the surgical process to ensure timely delivery to the patient; on the other hand it delivers precisely the right amount of blood through a personalized program, avoiding any possible harm caused by excessive infusion to the patient.

Haier Biomedical has completed its transformation from the world's prominent full cold chain brand to an IoT-ready biotechnology platform ecosystem. And it has taken the lead in creating the U-Blood platform to eliminate the "information silo" by connecting hospitals, blood centers and governments, which enables the interoperability, traceability, and information sharing of all the blood resources. Being innovative with the move to transfer blood bank to the patient's bedside and the ability to deliver the precise amount of blood needed, the solution ultimately enables an evolution in user experience with the implementation of the ecosystem. Furthermore, in the future, this ecosystem can be extended to a 5U biotechnology platform - a Haier Biomedical's platform bringing together the blood, biobank, vaccine, reagent and stem cell solutions, which can efficiently accelerate the development of the global healthcare sector.

Notably, the Rendanheyi management model has played a leading role in the creation of Haier Biomedical's platform ecosystem. Recognized as the first-of-its-kind and a revolutionary management model since the third industrial revolution, Rendanheyi has guided Haier Biomedical to transform from an equipment exporter to a business incubator. By integrating the ecosystem, the revenue derived from the ecosystem and the brand associated, the concept has also proven itself as a good fit for the business model which is ready for the world of IoT. Last but not least, recognized by international authorities and research institutions, it is now an exemplar of a management model with universal applicability and social benefits, which it has been.

SOURCE Haier